Background Depression remains a leading cause of disability and suicide worldwide, with treatment-resistant depression (TRD) affecting nearly 30% of individuals diagnosed with major depressive disorder. Esketamine nasal spray (NS) and quetiapine extended-release (XR) are both approved as adjunctive therapies for TRD; however, direct head-to-head comparisons are limited. Method A systematic...
Background Though esketamine was approved by the Food and Drug Administration (FDA) for treatment-resistant depression in 2019, there is no published research on implementation challenges. Therefore, the aim of this study was to investigate online commentary about these challenges among mental healthcare providers. Methods Using the terms “esketamine” and “Spravato”, the author searched social...
BACKGROUND: Postpartum depression (PPD) is a severe, debilitating mood disorder with consequences for both mothers and children, highlighting the need for rapid-acting and effective treatments for PPD. The aim of this narrative review is to synthesize the available literature on the administration of ketamine for PPD and propose ketamine as a viable and advantageous treatment. METHODS: A search...
BACKGROUND: 3,4-Methylenedioxymethamphetamine (MDMA or Ecstasy) is a synthetic amphetamine analogue that is recreationally used to obtain a psychological effect of enhanced affiliative emotional response. Its use in Western countries appears to be increasing, particularly among young individuals. METHODS: Pertinent basic and clinical literature is critically reviewed. RESULTS: A significant...